Shield Therapeutics plc (STX) Ordinary Shares 1.5p
- Add to watchlist
- Create an alert
- This stock can be held in a
Share news, reports & tips
-
Shield Therapeutics announces promising paediatric trial results
25 September 2024 14:56
(Sharecast News) - Shield Therapeutics announced promising results from its phase three paediatric clinical trial for 'Accrufer' and 'Ferracru', or ferric maltol, in treating iron...
-
Shield Therapeutics iron deficiency treatment approved in Canada
27 August 2024 12:28
(Sharecast News) - Commercial-stage pharmaceutical company Shield Therapeutics announced on Tuesday that 'ACCRUFeR', or ferric maltol, had been approved by Health Canada as a prescription drug for...
-
Shield Therapeutics net sales grow in Q2, CEO stands down
24 July 2024 09:15
(Sharecast News) - Commercial-stage pharmaceutical company Shield Therapeutics said on Wednesday that total net sales had grown in Q2, driven by "robust" increases in prescriptions and higher net...
-
Shield Therapeutics reports strong US progress
7 December 2023 13:11
(Sharecast News) - Iron deficiency-focussed pharmaceuticals company Shield Therapeutics announced significant achievements in the US commercialisation of Accrufer on Thursday.
-
Shield's Canadian partner files new drug submission for Accrufer
21 March 2022 11:58
(Sharecast News) - Commercial-stage pharmaceutical company Shield Therapeutics announced on Monday that KYE Pharmaceuticals has submitted a new drug submission to Health Canada, for the regulatory review and...
-
Shield Therapeutics revenue falls in line with expectations
17 February 2022 15:51
(Sharecast News) - Commercial-stage pharmaceutical company Shield Therapeutics reported total 2021 revenue of £1.5m in a trading update on Thursday, in line with market expectations.
-
Shield Therapeutics enters Accrufer licensing deal in Canada
5 January 2022 13:43
(Sharecast News) - Commercial-stage pharmaceutical company Shield Therapeutics has entered into an exclusive licence agreement for 'Accrufer', it announced on Wednesday, with KYE Pharmaceuticals in...
-
Shield shares surge on expansion of US coverage for Accrufer
16 December 2021 15:21
(Sharecast News) - Commercial-stage pharmaceutical company Shield Therapeutics updated the market on progress made on payer coverage of 'Accrufer' in the United States on Thursday.
-
Shield Therapeutics appoints chief medical officer
27 September 2021 14:26
(Sharecast News) - Commercial-stage pharmaceutical company Shield Therapeutics announced on Monday that Dr Jose Menoyo is joining its senior executive team as vice-president and chief medical officer, with...
Company announcements Announcements
-
Results from Phase 3 paediatric study
25 September 2024 07:00
Shield Therapeutics
-
Hardman & Co Research on Shield Therapeutics (STX): Focusing on successful execution
11 September 2024 12:25
Shield Therapeutics
-
Interim results
4 September 2024 07:00
Shield Therapeutics
-
ACCRUFeR® Approved by Health Canada
27 August 2024 07:00
Shield Therapeutics
-
Notice of interim results
14 August 2024 07:00
Shield Therapeutics
-
Unaudited Q2 2024 Trading Update
24 July 2024 07:01
Shield Therapeutics
-
Directorate Change
24 July 2024 07:00
Shield Therapeutics
-
$5.7m Milestone Monetization Agreement with AOP
3 July 2024 07:00
Shield Therapeutics
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.